Laddar populära aktier...
Q3 with healthy 7% organic growth despite headwinds Growth and cost improvement yields 300bp margin expansion EPS +3-5% and FVR up to DKK 30...
Q3 EBITDA +5-6% and Net Profit +12-21% Guidance unchanged as expected Checkmark on Q3, while we await US Medicare in 2025 Q3'24 in numbers ...
Solid Q3e with 7% organic growth and 22% EBITDA growth US market could be sluggish again, but focus is on 2025 We reiterate our fair value r...
- 6% organic growth despite headwinds in major markets - Strong margins highlight low guidance into H2 - EPS +3-6%, FVR hiked to DKK 27-40 (...
- Q2 EBITDA beating by 9-13% on product mix, scale and cost focus - Guidance hiked despite continued US market sluggishness - Expect +5% Con...
- Medicare expands lower-limb prosthetics coverage from 1 Sep - Good news for patients and Embla Medical - P&L implications unclear, but loo...
Q2 report due Tuesday, 23 July – many moving parts Key factor looks to be possible imminent Medicare news Updated fair value range DKK 26-38...
Solid 7% organic growth in Q1, underlying was even better Another $3m in restructuring costs reveals margin pressure We maintain our FV rang...
Fine 7% Group organic growth which could have been better No news on CMS reimbursement, Guidance adds $4m one-off costs Consensus a few % do...
- Embla (name change from Ossur) reports Q1 on 23 April in morning - Solid start to 2024 with 5% Q1e organic growth, held back by tough comp...
Ossur reported strong growth and weak margins in Q4 New Medicare reimbursement could have substantial positive impact We narrow fair value r...
Q4e: Tuesday, 30 January at 8:00 CET Healthy 2024 with 6% organic growth and solid margin expansion Fair value reiterated at DKK 26-40 Q4 T...
Solid Q3 with 7% organic growth and 8% EBITDA beat vs.
Q3 7% organic growth and $36m (+1-8% vs expectations) 2023 Guidance unchanged, very wide implicit Q4 Solid margins and cash flow generation,...
Q3 report due Tuesday, 24 October Q3e: solid 6% org.
• Solid Q2'23, providing confidence to upgrade FY'23.
- Q2 likely a solid but uneventful quarter - ......
Solid Q1, in line with consensus Strategic case remains unchanged after recent CMD No estimate changes, fair value remains at DKK 24-54 Sal...
Q1'23e should be solid... .. but few strategic updates likely after CMD in March Therefore, the report should be neutral for the share ABGS...
Solid growth ambitions released ahead of CMD tomorrowFY'23 guidance reiterated, as expectedOverall, share likely to trade up tomorrow5y LYC ...
FY'23 guidance indicates slow margin pick-up CMD in March should confirm intact LT outlook Fair value range of DKK 24-54 reiterated Margin ...
Solid Q4 top-line, but margins fail to reach expectations FY'23 guidance indicates a soft margin expansion outlook We expect the share to tr...
Cons. expects FY'22 org growth of 3.8% vs. guidance of 4-6% China reopening likely not a major cons.
As pre-announced, Q2 sales weaker than expected FY’22 revenue/EBITDA guidance downgraded Fair value range reiterated at DKK 26-56 Weak US/...
Organic growth down to 4-6% (cons. 6.2%) EBITDA down to 18-20% (cons.
Volatile APAC and cost base negatively impacting Q2 We expect FY’22 EBITDA guidance to be under pressure Fair value range down to DKK 26-56 ...
Despite Q1’22 being slightly weaker than consensus.
Q1’22 organic rev. growth of 6% (cons. 8%) FY’22 guidance reiterated, indicating back-end loaded FY We expect a slightly negative share rea...
Considerable cuts in travel expense expected long-term Today we had the pleasure of hosting CEO Jon Sigurdsson, for our ABGSC conference cal...
All key markets saw strong sales recovery in Q2’21 Ôssur reported a strong Q2’21 with sales of USD 190m (vs.
